Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23749719 | 0.81 | CYP1A1 (0.31) | L3MBTL1 | |
| SCHEMBL1637009 | 0.80 | ALOX5 (0.44) | L3MBTL1DYRK1AALOX5CASP3SENP7 | |
| SCHEMBL25595286 | 0.79 | ALOX5 (0.36) | ALOX5 | |
| SCHEMBL22908129 | 0.77 | L3MBTL1 (0.39) | L3MBTL1ALOX5MAPT | |
| SCHEMBL21150182 | 0.77 | CDK9 (0.35) | L3MBTL1CDK9DYRK1ADYRK2 | |
| SCHEMBL26309469 | 0.76 | CYP1A1 (0.32) | — | |
| SCHEMBL25120354 | 0.76 | PGR (0.35) | L3MBTL1CDK9DYRK1ADYRK2 | |
| SCHEMBL22617891 | 0.76 | L3MBTL1 (0.40) | L3MBTL1CDK9DYRK1ADYRK2HSP90AA1 | |
| SCHEMBL20071932 | 0.75 | L3MBTL1 (0.36) | L3MBTL1CDK9DYRK1ADYRK2HSP90AA1 | |
| SCHEMBL25513805 | 0.75 | HSP90AA1 (0.32) | ALOX5HSP90AA1HSP90AB1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11069862-B2 | Material for organic electroluminescence device and organic electroluminescence device using the same | IDEMITSU KOSAN CO., LTD. (JP) | 2021-07-20 | — | — | US | disclosed |
| US-20180083205-A1 | MATERIAL FOR ORGANIC ELECTROLUMINESCENCE DEVICE AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11069862-B2 | Material for organic electroluminescence device and organic electroluminescence device using the same | EPCAM, ILK, PPOX | L3MBTL1 629/4885CDK9 1672/4885DYRK1A 3424/4885 |
| US-20180083205-A1 | MATERIAL FOR ORGANIC ELECTROLUMINESCENCE DEVICE AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | EPCAM, ILK, PPOX | L3MBTL1 604/4885CDK9 1694/4885DYRK1A 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.